Current disease phase-Early chronic phase Posts on Medivizor

The link between treatment outcomes and quality of life in patients with chronic myeloid leukemia under tyrosine kinase inhibitor therapy

Posted by Medivizor on May 3, 2020 in Leukemia | 0 comments

In a nutshell The study examined whether health-related quality of life (HRQoL) relates to the molecular response (MR) to tyrosine kinase inhibitors (TKIs) in patients with chronic-phase chronic myeloid leukemia (CP-CML). The authors found that improved MR had differential effects on HRQoL in such patients. Some background TKIs are a treatment used...

Evaluating a method to predict the outcomes of patients with chronic myeloid leukemia treated with imatinib

Posted by Medivizor on Mar 28, 2020 in Leukemia | 0 comments

In a nutshell The study tested whether the EUTOS long-term survival (ELTS) score is efficient to evaluate treatment response in patients with chronic myeloid leukemia (CML), treated with imatinib (Gleevec). The main finding was that ELTS could effectively predict treatment outcomes among such patients in the real world. Some background Initial...

The effects of treatment switching from imatinib to nilotinib in patients with chronic phase-chronic myeloid leukemia

Posted by Medivizor on Feb 29, 2020 in Leukemia | 0 comments

In a nutshell The study investigated the effects of switching treatment to nilotinib (Tasigna) after initial therapy with imatinib (Gleevec) in patients with chronic phase of chronic myeloid leukemia (CP-CML). The authors found that switching to nilotinib after imatinib initial treatment is convenient and effective in such patients. Some background...

Which factors affect the safety and effectiveness of imatinib treatment for newly diagnosed chronic myeloid leukemia?

Posted by Medivizor on Jan 7, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of imatinib treatment in patients with newly diagnosed chronic myeloid leukemia. This study concluded that patients of lower weight and older age are more vulnerable to side effects. Some background Imatinib (Gleevec) is a targeted therapy...

A look at treatment responses and the possibility of stopping imatinib

Posted by Medivizor on Mar 11, 2018 in Leukemia | 0 comments

In a nutshell This study examined treatment responses to imatinib (Glivec) in chronic myeloid leukemia (CML) patients. Researchers reported that about half of patients achieved an optimal response to treatment that could allow patients to safely stop therapy. Some background Molecular response (MR) is a response to treatment where hardly any or no...

Nilotinib versus dasatinib: Comparing side effects

Posted by Medivizor on Feb 23, 2018 in Leukemia | 0 comments

In a nutshell This study compared side effects between two similar therapies – nilotinib (Tasigna) and dasatinib (Sprycel) – for chronic myeloid leukemia (CML). Researchers reported more serious side effects with dasatinib than with nilotinib. Some background Tyrosine kinase inhibitor (TKI) therapy is a standard first-line treatment...

An overview of the dose management of dasatinib

Posted by Medivizor on Feb 5, 2018 in Leukemia | 0 comments

In a nutshell This study reviewed evidence on the dose management of dasatinib (Sprycel) for chronic myeloid leukemia (CML). Some background Tyrosine kinase inhibitor (TKI) therapy is a standard first-line treatment for CML. Many patients achieve optimal response to TKI therapy and have a near-normal life expectancy. However, this response is lost...

Chromosomal abnormalities at diagnosis does not predict long-term treatment outcomes with tyrosine kinase inhibitors

Posted by Medivizor on Jan 28, 2018 in Leukemia | 0 comments

In a nutshell This study examined whether chromosomal abnormalities at diagnosis can predict treatment outcomes with TKIs in chronic myeloid leukemia (CML). Researchers reported similar long-term treatment outcomes in patients with and without chromosomal abnormalities at diagnosis. Some background CML is a disease in which the bone marrow makes...

Switching between tyrosine kinase inhibitors: 2-year follow-up of nilotinib after imatinib

Posted by Medivizor on Jan 12, 2018 in Leukemia | 0 comments

In a nutshell This study examined outcomes of nilotinib (Tasigna) as a second-line therapy over 2 years in patients with chronic myeloid leukemia (CML). The results of this observational study add valuable information to the body of evidence on the effectiveness of nilotinib after imatinib in patients with chronic-phase CML. Some background...

Remission rates after discontinuation of imatinib

Posted by Medivizor on Nov 7, 2017 in Leukemia | 0 comments

In a nutshell This study examined outcomes after discontinuation of imatinib (Gleevac) in patients with chronic myeloid leukemia (CML). Researchers reported that some CML patients can safely discontinue imatinib after achieving a deep treatment response. Factors such as detectable residual leukemia cells after treatment affect the risk of losing...

Safe to switch to imatinib for long-term use after initial treatment with nilotinib or dasatinib

Posted by Medivizor on Nov 6, 2017 in Leukemia | 0 comments

In a nutshell This study examined whether switching between tyrosine kinase inhibitor (TKI) therapy is safe and effective for patients with chronic myeloid leukemia (CML). This study concluded that after achieving optimal response with a second-generation TKI such as dasatinib (Sprycel) or nilotinib (Tasigna), treatment can be safely switched to...

Modern treatment approaches for chronic-phase CML

Posted by Medivizor on Oct 25, 2017 in Leukemia | 0 comments

In a nutshell This study reviewed evidence of novel agents in the treatment of chronic myeloid leukemia (CML). Some background CML is a disease in which the bone marrow makes too many mature and immature white blood cells. It is typically a slowly progressing disease that occurs mainly during or after middle age. Most patients are diagnosed in the...

Current disease phase-Early chronic phase Posts on Medivizor

The link between treatment outcomes and quality of life in patients with chronic myeloid leukemia under tyrosine kinase inhibitor therapy

Evaluating a method to predict the outcomes of patients with chronic myeloid leukemia treated with imatinib

The effects of treatment switching from imatinib to nilotinib in patients with chronic phase-chronic myeloid leukemia

Which factors affect the safety and effectiveness of imatinib treatment for newly diagnosed chronic myeloid leukemia?

A look at treatment responses and the possibility of stopping imatinib

Nilotinib versus dasatinib: Comparing side effects

An overview of the dose management of dasatinib

Chromosomal abnormalities at diagnosis does not predict long-term treatment outcomes with tyrosine kinase inhibitors

Switching between tyrosine kinase inhibitors: 2-year follow-up of nilotinib after imatinib

Remission rates after discontinuation of imatinib

Safe to switch to imatinib for long-term use after initial treatment with nilotinib or dasatinib

Modern treatment approaches for chronic-phase CML

Categories

Recent Posts

Archives

Current disease phase-Early chronic phase Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email